Colleen Cutcliffe, PhD, is co-founder and CEO of , a biotech startup in San Francisco. Colleen stands alone among entrepreneurs: she is a scientist with a doctoral degree in biochemistry and molecular biology, a pioneer in the exploration of the human...
Colleen Cutcliffe, PhD, is co-founder and CEO of Pendulum Therapeutics, a biotech startup in San Francisco. Colleen stands alone among entrepreneurs: she is a scientist with a doctoral degree in biochemistry and molecular biology, a pioneer in the exploration of the human body’s microbiome, and a challenger of the probiotics industry and its 1970s-era formulas.
Prior to Pendulum, Colleen led a team of scientists at Pacific Biosciences, a company famous for its DNA sequencing. Armed with this technology, Pendulum is doing groundbreaking microbiome research by extracting new bacterial strains, studying their impact on chronic conditions, and combining them in never-before-seen formulations. The company’s mission is to create probiotics as effective as prescription drugs, without any side effects. The company’s first offering, Pendulum Glucose Control, is the only probiotic in existence that has lowered blood sugar spikes and A1C levels in a clinical trial – welcome news for the 122 million Americans living with diabetes and prediabetes.
Colleen completed her postdoctoral research at Northwestern Medicine’s Lurie Children's Hospital of Chicago. She received a doctoral degree in biochemistry and molecular biology from Johns Hopkins University and a bachelor’s degree in biochemistry from Wellesley College.
Some of the Topics Covered by Colleen Cutcliffe in this Episode
Sign up for The Grind, for actionable insights and stories from successful entrepreneurs delivered to your inbox once per week: https://www.justgogrind.com/newsletter/
Listen to all episodes of the Just Go Grind Podcast: https://www.justgogrind.com/podcast/
Follow Justin Gordon on Twitter: https://twitter.com/justingordon212
Follow Justin Gordon on Instagram: https://www.instagram.com/justingordon8/